The FDA on Tuesday said it is planning on doing more surprise inspections of foreign factories, a day after Trump signed an ...

NewLimit raises $130M Series B led by Kleiner Perkins to advance epigenetic reprogramming research for liver disease ...

Vertex paused an early-stage trial of its inhaled treatment for cystic fibrosis that came from a partnership with Moderna.

Plus, news about Atara Bio­ther­a­peu­tics, Im­mutep, blue­bird bio, OSE Im­munother­a­peu­tics, Mer­sana Ther­a­peu­tics, ...

Aldeyra Therapeutics reports Phase 3 success with reproxalap for dry eye disease, plans third FDA filing after previous ...

A Singapore-based startup raised a $45 million Series B to start testing a gene therapy in humans next year for a genetic ...

Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...

Function Health is buying Ezra in a bid to create a haven for people who want copious amounts of data on their bodies. The ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...

Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new ...

FDA delays Stealth BioTherapeutics PDUFA date amid questions about agency disruption, while other companies like Sanofi and J ...